The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.
 
Jacqueline V. Aredo
No Relationships to Disclose
 
Anatoly Urisman
Consulting or Advisory Role - Pliant
 
Matthew A. Gubens
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cardinal Health; Genentech/Roche; Genzyme; Guardant Health; ITeos Therapeutics; Sanofi; Surface Oncology
Research Funding - Amgen; Celgene (Inst); Genentech/Roche (Inst); Johnson & Johnson/Janssen; Merck (Inst); Novartis (Inst); OncoMed (Inst); Trizell (Inst)
 
Claire Mulvey
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Genentech
 
Greg M. Allen
No Relationships to Disclose
 
Julia K. Rotow
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Gritstone Bio; Guardant Health; Janssen; Lilly; Sanofi/Regeneron; Takeda
Travel, Accommodations, Expenses - AstraZeneca
 
Daniel Lucas Kerr
No Relationships to Disclose
 
Turja Chakrabarti
No Relationships to Disclose
 
Bianca Bacaltos
No Relationships to Disclose
 
Megan Gee
No Relationships to Disclose
 
Kirk Jones
No Relationships to Disclose
 
Dara L. Aisner
No Relationships to Disclose
 
Tejas Patil
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Elevation Oncology; Janssen; Mirati Therapeutics; Pfizer; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - EMD Serono; Janssen
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Erin Lynn Schenk
Honoraria - Horizon CME; Ideology Health; MECC Global Meetings; MJH Life Sciences; OncLive; OncLive; Regeneron; Takeda
Consulting or Advisory Role - Actinium Pharmaceuticals; Bionest partners; ClearView Healthcare Partners; G1 Therapeutics; Guidepoint Global; Prescient Healthcare Group; Regeneron; Regeneron
 
Trever G. Bivona
Stock and Other Ownership Interests - Driver, Inc
Honoraria - Array BioPharma; AstraZeneca; Novartis; Revolution Health Care
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Novartis; Revolution Health Care
Speakers' Bureau - Novartis
Research Funding - Ignyta; Novartis; Revolution Health Care
 
Jonathan W. Riess
Consulting or Advisory Role - Bayer; BeiGene; Biodesix; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; EMD Serono; Genentech; Janssen Oncology; Jazz Pharmaceuticals; Merus NV; Novartis; Regeneron; Sanofi; Seagen; Summit pharmaceuticals; Turning Point Therapeutics
Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Melissa Coleman
No Relationships to Disclose
 
Johannes Ruediger Kratz
Stock and Other Ownership Interests - OncoCyte
Speakers' Bureau - OncoCyte
Patents, Royalties, Other Intellectual Property - University of California, San Francisco
 
David Jablons
No Relationships to Disclose
 
Collin M. Blakely
Honoraria - Aptitude Health; Axiom Healthcare Strategies; Clarion Healthcare
Consulting or Advisory Role - Blueprint Medicines; Janssen Oncology; OncoCyte
Research Funding - AstraZeneca (Inst); Cellectis (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)